equine herpes virus-4 thymidine-kinase-vaccine; expression in mammal host transformant; dna...

1
Patent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from 'Biotechnology Abstracts' with permission of Derwent Publications Ltd., Rochdale House, 128 Theobalds Road, London WC1X 8RD. Telephone 071 242 5823; Fax 071 405 3630. New rotaviros reassortants as vaccine components; containing human rotavirus VP4 and/or VP7 neutralization antigen gene and cattle rotaviros gene; isolation from infected CV-1, Vero, BSC-1, MA104, etc. cell culture Wistar Inst. Anat. Biol. World 9201 784; 6 February 1992 A rotavirus (RV) reassortant contains human RV gene 4 and another gene encoding the VP4 and VP7 neutralization antigens. The remaining RV segments originate from cattle RV WC3 or human and cattle RV. The reassortant induces a protective immune response in human adult and infant patients to challenge with native RV, without producing serious adverse effects. The human RV is selected from serotypes 1, 2, 3, 4, 8 and 9. Both the VP7 and VP4 genes may be obtained from the same human RV strain e.g. RV W179-4, 9 contains human RV W170 genes 4 and 9 and cattle RV WC3 genes 1-3, 5-8. Also claimed are: RV reassortant WLSC2-4 (contains human RV SC2 serotype 2 gene 4 and remaining genes from cattle RV WC3); and a vaccine comprising the RV reassortant and protecting against acute diarrhoea caused by human RV. Preparation of reassortant RT involves: infecting e.g. CV-1, Vero, BSC-1, MA104 or primary primate kidney cells with cattle RV WC3 and human RV under conditions enabling gene reassortment; and examining the progeny clones from plaques by PAGE for the presence of a reassortant containing VP4 and VP7 genes from human RV. 073-92 Equine herpes virus-4 thymidine-kinase-vaccine; expression in mammal host transformant; DNA sequence; potential mono- valent, multivalent live recombinant vaccine vector Merck USA Eur 471 407; 19 February 1992 A horse herpes virus-4 (EHV-4) thymidine-kinase (TK, EC 2.7.1.21 )-deficient mutant which has a deletion and/or insertion in the TK gene, is claimed. Also claimed are: i. a recombinant vector plasmid (I) comprising a vector and part of the EHV-4 TK gene region; ii. a host cell (e.g. rabbit cells, horse dermal cells, etc. ) containing (I); iii. preparation of an EHV-4 mutant by co-transfecting a cell culture with EHV-4 DNA in (I); and iv. a cell culture infected with the mutant. In a preferred mutation, the ends of the deletion or insertion region do not correspond to endonuclease restriction sites of the TK gene, and the region is preferably in the C-terminal coding region of TK. At least one heterologous DNA sequence encoding a protein is inserted under the control of a promoter that regulates expression in cells infected with the EHV-4 mutant. The sequence encodes an antigen of a horse pathogen, preferably of EHV-1 or horse influenza virus. The mutant may be used as a vaccine for horses susceptible to EHV-4. It may also be used to produce subunit vaccines, pharmaceuticals and diagnostic preparations. 074-92 New antigenic conjugate of HIV virus major neutralization determinant; complex with Neisseria meningitidis outer membrane proteosome application in AIDS, AIDS-related complex therapy, recombinant vaccine Univ. Glasgow; Equine Virol. Res. Found. World 9201 045; 23 January 1992 New amino acid sequences of an envelope fragment of HIV are disclosed, as well as immunological conjugates for use in AIDS and AIDS related complex (ARC) vaccines. The conjugates comprise HIV major neutralization determinant (PND) covalently linked, by a bienergetic spacer, to purified outer membrane proteosome (Omp) of Neisseria (preferably Neisseria meningitidis): (PND)n-(Omp), where n = the number of PND proteins covalently lined to Omp (1-50), PND may be formed of peptides of 5-35 amino acids containing the sequence Gly-X-Gly (X = Pro, Leu, Ala, Gin or Ser, preferably Pro). PND is prepared by expressing an artificial gene in Escherichia coli. Omp is isolated from N. meningitidis, N-acetylhomocystaminylated and reacted with N-omega- bromoacetylated PND. The conjugate may be formulated with virucide, immunostimulant, immunosuppres sive, or anti- infective compounds, or with vaccines. An AIDS recombinant vaccine comprising the antigenic conjugate or cocktail of antigenic conjugates is specifically claimed for ARC or AIDS prevention. The conjugates are effective pre- or post-infection. 075-92 DNA sequence encoding bovine respiratory-syncytial virus G, F and N protein; used to produce recombinant protein and antibody; recombinant vaccine; diagnosis of virus infection UAB Res. Found. World 9201 471; 6 February 1992 Recombinant DNA molecules (I), (II) and (III) comprising specified DNA sequences encoding cattle respiratory-syncytial (BRS) virus proteins G, F and N, respectively, are claimed. Also new are: (1) recombinant microorganisms containing (I)-(III); (2) eukaryotic cells containing (I)-(III); (3) production of BRS virus G, F and N proteins or fragments by culturing (1) or (2); (4) G, F and N proteins and fragments; (5) subunit vaccines comprising the proteins/fragments of (4) in pharmaceutical carriers; (6) recombinant viruses which are infectious but nonpathogenic and which comprise DNA molecules (I)- (III); (7) recombinant or synthetic BRS virus G, F, and N proteins or subsequences comprising antigenic determinants having specified protein sequences; and (8) subunit vaccines comprising the proteins of (7). (I), (II) and (III) are contained in plasmid pRLG414-76-191 (ATCC 40841), plasmid pRLF2012-76-1902 (ATCC 40842) and plasmid pRLNB3-76 (ATCC 40843), respectively. For expression, a regulatory sequence is also included, and resulting molecules are contained in rVG642 (ATCC VR2276) and rVF-464 (ATCC VR2277) for (I) and (II), respectively. 076-92 New immunogenic peptide sequence from Echinococeus granulosus; useful in recombinant vaccine, diagnosis of hydatidosis; DNA sequence, vector, monoclonal antibody, hybridoma Inst. Pasteur," Inst. Pasteur Lille; INSERM World 9201 051; 23 January 1992 A new immunogenic peptide sequence (I) from Echinococcus granulosus antigen 5 is recognized by sera of hydatidosis patients and by IgG 1 monoclonal antibodies (MAbs) produced 0264-410X/92/100721-02 © 1992 Butterworth-Heinemann Ltd Vaccine, Vol. 10, Issue 10, 1992 721

Post on 23-Nov-2016

212 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Equine herpes virus-4 thymidine-kinase-vaccine; expression in mammal host transformant; DNA sequence; potential monovalent, multivalent live recombinant vaccine vector

Patent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from 'Biotechnology Abstracts' with permission of Derwent Publications Ltd., Rochdale House, 128 Theobalds Road, London WC1X 8RD. Telephone 071 242 5823; Fax 071 405 3630.

New rotaviros reassortants as vaccine components; containing human rotavirus VP4 and/or VP7 neutralization antigen gene and cattle rotaviros gene; isolation from infected CV-1, Vero, BSC-1, MA104, etc. cell culture Wistar Inst. Anat. Biol. World 9201 784; 6 February 1992

A rotavirus (RV) reassortant contains human RV gene 4 and another gene encoding the VP4 and VP7 neutralization antigens. The remaining RV segments originate from cattle RV WC3 or human and cattle RV. The reassortant induces a protective immune response in human adult and infant patients to challenge with native RV, without producing serious adverse effects. The human RV is selected from serotypes 1, 2, 3, 4, 8 and 9. Both the VP7 and VP4 genes may be obtained from the same human RV strain e.g. RV W179-4, 9 contains human RV W170 genes 4 and 9 and cattle RV WC3 genes 1-3, 5-8. Also claimed are: RV reassortant WLSC2-4 (contains human RV SC2 serotype 2 gene 4 and remaining genes from cattle RV WC3); and a vaccine comprising the RV reassortant and protecting against acute diarrhoea caused by human RV. Preparation of reassortant RT involves: infecting e.g. CV-1, Vero, BSC-1, MA104 or primary primate kidney cells with cattle RV WC3 and human RV under conditions enabling gene reassortment; and examining the progeny clones from plaques by PAGE for the presence of a reassortant containing VP4 and VP7 genes from human RV. 073-92

Equine herpes virus-4 thymidine-kinase-vaccine; expression in mammal host transformant; DNA sequence; potential mono- valent, multivalent live recombinant vaccine vector Merck USA Eur 471 407; 19 February 1992

A horse herpes virus-4 (EHV-4) thymidine-kinase (TK, EC 2.7.1.21 )-deficient mutant which has a deletion and/or insertion in the TK gene, is claimed. Also claimed are: i. a recombinant vector plasmid (I) comprising a vector and part of the EHV-4 TK gene region; ii. a host cell (e.g. rabbit cells, horse dermal cells, etc. ) containing (I); iii. preparation of an EHV-4 mutant by co-transfecting a cell culture with EHV-4 DNA in (I); and iv. a cell culture infected with the mutant. In a preferred mutation, the ends of the deletion or insertion region do not correspond to endonuclease restriction sites of the TK gene, and the region is preferably in the C-terminal coding region of TK. At least one heterologous DNA sequence encoding a protein is inserted under the control of a promoter that regulates expression in cells infected with the EHV-4 mutant. The sequence encodes an antigen of a horse pathogen, preferably of EHV-1 or horse influenza virus. The mutant may be used as a vaccine for horses susceptible to EHV-4. It may also be used to produce subunit vaccines, pharmaceuticals and diagnostic preparations. 074-92

New antigenic conjugate of HIV virus major neutralization determinant; complex with Neisseria meningitidis outer membrane proteosome application in AIDS, AIDS-related complex therapy, recombinant vaccine Univ. Glasgow; Equine Virol. Res. Found. World 9201 045; 23 January 1992

New amino acid sequences of an envelope fragment of HIV are disclosed, as well as immunological conjugates for use in AIDS and AIDS related complex (ARC) vaccines. The conjugates comprise HIV major neutralization determinant (PND) covalently linked, by a bienergetic spacer, to purified outer membrane proteosome (Omp) of Neisseria (preferably Neisseria meningitidis): (PND)n-(Omp), where n = the number of PND proteins covalently lined to Omp (1-50), PND may be formed of peptides of 5-35 amino acids containing the sequence Gly-X-Gly (X = Pro, Leu, Ala, Gin or Ser, preferably Pro). PND is prepared by expressing an artificial gene in Escherichia coli. Omp is isolated from N. meningitidis, N-acetylhomocystaminylated and reacted with N-omega- bromoacetylated PND. The conjugate may be formulated with virucide, immunostimulant, immunosuppres sive, or anti- infective compounds, or with vaccines. An AIDS recombinant vaccine comprising the antigenic conjugate or cocktail of antigenic conjugates is specifically claimed for ARC or AIDS prevention. The conjugates are effective pre- or post-infection.

075-92

DNA sequence encoding bovine respiratory-syncytial virus G, F and N protein; used to produce recombinant protein and antibody; recombinant vaccine; diagnosis of virus infection UAB Res. Found. World 9201 471; 6 February 1992

Recombinant DNA molecules (I), (II) and (III) comprising specified DNA sequences encoding cattle respiratory-syncytial (BRS) virus proteins G, F and N, respectively, are claimed. Also new are: (1) recombinant microorganisms containing ( I ) - ( I I I ) ; (2) eukaryotic cells containing ( I ) - ( I I I ) ; (3) production of BRS virus G, F and N proteins or fragments by culturing (1) or (2); (4) G, F and N proteins and fragments; (5) subunit vaccines comprising the proteins/fragments of (4) in pharmaceutical carriers; (6) recombinant viruses which are infectious but nonpathogenic and which comprise DNA molecules ( I ) - (III); (7) recombinant or synthetic BRS virus G, F, and N proteins or subsequences comprising antigenic determinants having specified protein sequences; and (8) subunit vaccines comprising the proteins of (7). (I), (II) and (III) are contained in plasmid pRLG414-76-191 (ATCC 40841), plasmid pRLF2012-76-1902 (ATCC 40842) and plasmid pRLNB3-76 (ATCC 40843), respectively. For expression, a regulatory sequence is also included, and resulting molecules are contained in rVG642 (ATCC VR2276) and rVF-464 (ATCC VR2277) for (I) and (II), respectively.

076-92

New immunogenic peptide sequence from Echinococeus granulosus; useful in recombinant vaccine, diagnosis of hydatidosis; DNA sequence, vector, monoclonal antibody, hybridoma Inst. Pasteur," Inst. Pasteur Lille; I N S E R M World 9201 051; 23 January 1992

A new immunogenic peptide sequence (I) from Echinococcus granulosus antigen 5 is recognized by sera of hydatidosis patients and by IgG 1 monoclonal antibodies (MAbs) produced

0264-410X/92/100721-02 © 1992 Butterworth-Heinemann Ltd Vaccine, Vol. 10, Issue 10, 1992 721